| Autor: |
Fionda, Laura, Lauletta, Antonio, Leonardi, Luca, Perez, Jorge Alonso, Morino, Stefania, Merlonghi, Gioia, Alfieri, Girolamo, Costanzo, Rocco, Tufano, Laura, Vanoli, Fiammetta, Rossini, Elena, Vigo, Eduard Gallardo, Tartaglione, Tommaso, Salvetti, Marco, Antonini, Giovanni, Diaz-Manera, Jordi, Garibaldi, Matteo |
| Předmět: |
|
| Zdroj: |
Journal of Neurology; Feb2023, Vol. 270 Issue 2, p960-974, 15p |
| Abstrakt: |
Objectives: Immune-mediated necrotizing myopathy (IMNM) is the most severe idiopathic inflammatory myopathy (IIM) and early aggressive poly-immunotherapy is often required to reduce long-term disability. The aim of this study is to investigate muscle MRI in IMNM as outcome measure for disease activity, severity, progression, response to treatment, and to better characterize the pattern of muscle involvement. Methods: This is a retrospective, observational, cross-sectional, and longitudinal study including 22 IMNM patients, divided into three groups based on timing of first MRI and if performed before or under treatment. T1 score and percentage of STIR positive muscles (STIR%) were considered and analyzed also in relation to demographic, clinical and laboratory characteristics. Results: STIR% was higher in untreated patients and in those who performed MRI earlier (p = 0.001). Pelvic girdle and thighs were in general more affected than legs. T1 score was higher in patients with MRI performed later in disease course (p = 0.004) with a prevalent involvement of the lumbar paraspinal muscles, gluteus medius and minimus, adductor magnus and hamstrings. 22% of STIR positive muscles showed fat replacement progression at second MRI. Higher STIR% at baseline correlated with higher risk of fat replacement at follow-up (p = 0.003); higher T1 score correlated with clinical disability at follow-up, with late treatment start and delayed treatment with IVIG (p = 0.03). Interpretation: Muscle MRI is a sensitive biomarker for monitoring disease activity and therapy response, especially when performed early in disease course and before treatment start, and could represent a supportive outcome measure and early prognostic index in IMNM. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink